Article
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
Hematological oncology - 1 Dec 2017
García-Sanz Ramón, Corchete Luis Antonio, Alcoceba Miguel, Chillon María Carmen, Jiménez Cristina, Prieto Isabel, García-Álvarez María, Puig Noemi, Rapado Immaculada, Barrio Santiago, Oriol Albert, Blanchard María Jesús, de la Rubia Javier, Martínez Rafael, Lahuerta Juan José, González Díaz Marcos, Mateos María Victoria, San Miguel Jesús Fernando, Martínez-López Joaquín, Sarasquete María Eugenia
Abstract excerpt
Bortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients. However, treatment-induced peripheral neuropathy (TiPN) is a common adverse event associated with them. Risk factors for TiPN in MM patients include advanced age, prior neuropathy, and other drugs, but there are conflicting results about the role of genetics in predicting the risk of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
